Fluctuation: Does blood pressure variability matter?

Circulation

Volumn 126, Issue 5, 2012, Pages 525-527

  Krakoff, Lawrence R ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

blood pressure; outcome assessment; treatment outcome; variability

Indexed keywords

ATENOLOL; LACIDIPINE;

ANTIHYPERTENSIVE THERAPY; ARTERIAL WALL THICKNESS; BLOOD PRESSURE FLUCTUATION; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; EDITORIAL; HOME MONITORING; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CIRCADIAN RHYTHM; DIHYDROPYRIDINES; FEMALE; HUMANS; HYPERTENSION; MALE; OFFICE VISITS;

EID: 84864456670     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.124750     Document Type: Editorial

References (19)

1. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143-1152.
2. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827-838. (Pubitemid 20113741)
3. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 2003. J Hypertens. 2003;21:1055-1076. (Pubitemid 36667856)
4. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895-905.
5. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive- drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375:906-915.
6. Kikuya M, Ohkubo T, Metoki H, Asayama K, Hara A, Obara T, Inoue R, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y. Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study. Hypertension. 2008;52:1045-1050.
7. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis. Circulation. 2012; 126:569-578.
8. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, Hansson L, Magnani B, Rahn KH, Reid J, Rodicio J, Safar M, Eckes L, Ravinetto R. Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. J Hypertens. 1998;16:949-961. (Pubitemid 28367949)
9. Zanchetti A, Hennig M, Baurecht H, Tang R, Cuspidi C, Carugo S, Mancia G. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. J Hypertens. 2007;25:2463-2470. (Pubitemid 350060385)
10. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, doubleblind, long-term trial. Circulation. 2002;106:2422-2427. (Pubitemid 35278796)
11. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability in the european lacidipine study on atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens. 2012;30:1241-1251.
12. Mancia G, Messerli F, Bakris G, Zhou Q, Champion A, Pepine CJ. Blood pressure control and improved cardiovascular outcomes in the international verapamil sr-trandolapril study. Hypertension. 2007;50: 299-305. (Pubitemid 47205777)
13. Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, Yusoff K, Ryden L, Liu GL, Teo K, Sleight P, Yusuf S. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011;124: 1727-1736.
14. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, Schwartz S. Predictors of adherence with antihypertensive and lipidlowering therapy. Arch Intern Med. 2005;165:1147-1152. (Pubitemid 40720739)
15. Kronish IM, Woodward M, Sergie Z, Ogedegbe G, Falzon L, Mann DM. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011;123:1611-1623.
16. Eigenbrodt ML, Rose KM, Couper DJ, Arnett DK, Smith R, Jones D. Orthostatic hypotension as a risk factor for stroke: the Atherosclerosis Risk in Communities (ARIC) study, 1987-1996. Stroke. 2000;31: 2307-2313.
17. Benvenuto LJ, Krakoff LR. Morbidity and mortality of orthostatic hypotension: implications for management of cardiovascular disease. Am J Hypertens. 2011;24:135-144.
18. Timmers HJ, Buskens FG, Wieling W, Karemaker JM, Lenders JW. Long-term effects of unilateral carotid endarterectomy on arterial baroreflex function. Clin Auton Res. 2004;14:72-79. (Pubitemid 38582289)
19. Muntner P, Joyce C, Levitan EB, Holt E, Shimbo D, Webber LS, Oparil S, Re R, Krousel-Wood M. Reproducibility of visit-to-visit variability of blood pressure measured as part of routine clinical care. J Hypertens. 2011;29:2332-2338.